Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Zawartość zarchiwizowana w dniu 2024-05-27

Exploring the diagnostics market for simple and fast point-of-care antibody detection

Cel

Antibody detection assays are used in many fields of biomedicine including the diagnosis of infectious diseases, autoimmune diseases and allergies. Current analytical techniques for antibody detection come with intrinsic limitations such as the requirement for multiple time-consuming incubation steps, multiple reagents, and/or sophisticated equipment. Supported by an ERC consolidator grant we have developed a highly modular sensor concept for antibody-responsive reporter enzymes (AbSens) that addresses many of these challenges. Key advantages include the ability to monitor antibodies directly in solution, easy read-out based on a simple color reaction, adaptability to target any antibody of interest, and high affinity and specificity. We believe that this generic sensor platform could find applications in low-cost point-of-care diagnostics, clinical research, and the development of therapeutic antibodies.

The goal of AbSens is to identify those opportunities in the huge market of antibody-based diagnostics where our sensor platform provides unique advantages over existing technologies, both in terms of analytical performance and economics.

To enable the next step towards commercialization, the analytical performance of our technology will be compared to current gold standards using relevant clinical samples in collaboration with commercial parties and clinicians. Other commercially important parameters are the long-term stability of the assay components and the development of a yeast-based production system to lower the cost of enzyme production. Based on an in-depth market analysis and the feedback we receive from external stakeholders on the performance of our technology, a realistic strategy will be developed for the further commercialization. In anticipation of exploring the commercialization of our AbSens technology we filed a US provisional patent application in Sept. 2012 on the key underlying technology, which was recently continued via the PCT route.

Zaproszenie do składania wniosków

ERC-2013-PoC
Zobacz inne projekty w ramach tego zaproszenia

Instytucja przyjmująca

TECHNISCHE UNIVERSITEIT EINDHOVEN
Wkład UE
€ 150 000,00
Adres
GROENE LOPER 3
5612 AE Eindhoven
Niderlandy

Zobacz na mapie

Region
Zuid-Nederland Noord-Brabant Zuidoost-Noord-Brabant
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Marjon Pijs (Mrs.)
Linki
Koszt całkowity
Brak danych

Beneficjenci (1)